TerminatedNCT04855747
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
This study evaluates the safety and effectiveness of REL-1017 for people with depression.
Medication studyAges 18–65United States
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of REL-1017 for people with depression.
Who could participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
- Listed locations
- Homewood and 69 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: March 30, 2021
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 236
- Sponsor
- Levomecor Inc.
- Sponsor type
- Other organization
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT04855747
- Official title
Show the full official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- Controlled Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment of Major Depressive Disorder (The RELIANCE-II Study)
Recruitment & locations
TerminatedHomewood · Chandler · Phoenix
59 more locations
- Tucson
- Bryant
- Anaheim
- Bellflower
- Encino
- Lafayette
- Los Angeles
- Newport Beach
- Orange
- Redlands
- Santa Ana
- Stanford
- Temecula
- Upland
- Denver
- Brandon
- Hialeah
- Jacksonville
- Maitland
- Miami
- Miami Springs
- Okeechobee
- Tampa
- West Palm Beach
- Savannah
- Boise
- Chicago
- Elgin
- Overland Park
- Marrero
- Baltimore
- Bel Air
- Gaithersburg
- Boston
- Bloomfield Hills
- Mankato
- Weldon Spring
- Las Vegas
- Toms River
- Cedarhurst
- Monroe
- Beachwood
- Cincinnati
- Westlake
- Philadelphia
- State College
- Memphis
- Austin
- Beaumont
- Bellaire
- Dallas
- Friendswood
- Houston
- Sherman
- Wichita Falls
- Draper
- Rutland
- Portsmouth
- Everett
A listed location does not confirm current availability.
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of REL-1017 for people with depression.
Who is behind this study?
The study sponsor is Levomecor Inc.
Does this study involve medication?
Yes. The study involves medication, including REL-1017 and Placebo.
Who can participate?
This study is for people with depression. Listed age limits: 18 years to 65 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as terminated.
Want to explore more studies?
Explore studiesRelated studies
16-week Comparative Effectiveness Trial of Lamotrigine vs. Fluoxetine for Depression in bipolarity
A Clinical Study of an Investigational Drug for the Treatment of Major Depressive Episode Associated With Bipolarity type I.